Teva Pharmaceuticals received U.S. Food and Drug Administration (FDA) approval for IGALMI® (dexmedetomidine) sublingual film for at-home use. It is the first FDA-approved medication adults can self-administer at home for the acute treatment of agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.
The approval addresses an unmet need for patients and caregivers by offering a way to manage disruptive agitation episodes outside a healthcare setting. Agitation affects an estimated 25% to 40% of people in these patient populations and can lead to emergency room visits or hospitalization.
The approval supports Teva’s growth strategy and follows the company’s acquisition of IGALMI from BioXcel Therapeutics in late October 2026. The FDA based its decision on positive results from the Phase 3 SERENITY At-Home trial, which demonstrated the treatment’s safety and tolerability in a non-clinical setting.